Free Trial
→ How he turns Zzzzzzz’s into $$$$$’s (From Timothy Sykes) (Ad) Buy GPCR Stock  Free GPCR Stock Alerts

Structure Therapeutics (GPCR) Financials

Structure Therapeutics logo
$22.20 -1.66 (-6.96%)
Closing price 04:00 PM Eastern
Extended Trading
$22.60 +0.40 (+1.78%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Structure Therapeutics

Annual Income Statements for Structure Therapeutics

This table shows Structure Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -122 -89 -53
Consolidated Net Income / (Loss)		 -123 -90 -51
Net Income / (Loss) Continuing Operations		 -123 -90 -51
Total Pre-Tax Income 		-122 -89 -51
Total Operating Income		 -158 -103 -53
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 158 103 53
Selling, General & Admin Expense		 49 33 16
Research & Development Expense		 109 70 36
Total Other Income / (Expense), net		 36 13 1.26
Interest Expense		 -36 -13 -1.26
Income Tax Expense		 0.31 0.24 0.02
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.39 -0.63 -
Basic Earnings per Share		 ($0.78) ($0.81) ($5.51)
Weighted Average Basic Shares Outstanding		 157.92M 110.20M 9.58M
Diluted Earnings per Share		 ($0.78) ($0.81) ($5.51)
Weighted Average Diluted Shares Outstanding		 157.92M 110.20M 9.58M
Weighted Average Basic & Diluted Shares Outstanding		 172.03M 139.79M -

Quarterly Income Statements for Structure Therapeutics

This table shows Structure Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -47 -39 -31 -26 -26 -24 -24 -23 -18 -12 -12
Consolidated Net Income / (Loss)		 -47 -36 -34 -26 -26 -25 -24 -23 -18 -12 -12
Net Income / (Loss) Continuing Operations		 -47 -36 -34 -26 -26 -25 -24 -23 -18 -12 -12
Total Pre-Tax Income 		-47 -36 -34 -26 -26 -25 -23 -23 -18 -12 -12
Total Operating Income		 -56 -47 -46 -33 -32 -31 -26 -26 -20 -13 -13
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 56 47 46 33 32 31 26 26 20 13 13
Selling, General & Admin Expense		 13 14 13 11 11 11 8.63 6.58 6.51 4.60 3.53
Research & Development Expense		 43 33 33 22 21 20 18 19 13 8.36 9.16
Total Other Income / (Expense), net		 9.58 11 12 7.34 6.01 6.18 2.69 2.83 1.70 0.90 0.35
Interest Expense		 -9.58 -11 -12 -7.34 -6.01 -6.18 -2.69 -2.83 -1.70 -0.90 -0.35
Income Tax Expense		 0.10 0.14 0.09 0.05 0.03 -0.31 0.41 0.12 0.03 -0.18 0.07
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.10 - -3.33 - - - - - - - -
Basic Earnings per Share		 ($0.27) ($0.21) ($0.20) ($0.18) ($0.19) ($0.15) ($0.21) ($0.20) ($0.25) ($1.16) ($1.27)
Weighted Average Basic Shares Outstanding		 172.05M 157.92M 171.63M 148.24M 139.71M 110.20M 114.95M 114.76M 71.66M 9.58M 9.78M
Diluted Earnings per Share		 ($0.27) ($0.21) ($0.20) ($0.18) ($0.19) ($0.15) ($0.21) ($0.20) ($0.25) ($1.16) ($1.27)
Weighted Average Diluted Shares Outstanding		 172.05M 157.92M 171.63M 148.24M 139.71M 110.20M 114.95M 114.76M 71.66M 9.58M 9.78M
Weighted Average Basic & Diluted Shares Outstanding		 172.61M 172.03M 171.78M 171.59M 139.86M 139.79M 139.16M 114.81M 114.80M 0.00 -

Annual Cash Flow Statements for Structure Therapeutics

This table details how cash moves in and out of Structure Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents		 40 104 -79
Net Cash From Operating Activities		 -117 -79 -46
Net Cash From Continuing Operating Activities		 -117 -79 -46
Net Income / (Loss) Continuing Operations		 -123 -90 -51
Consolidated Net Income / (Loss)		 -123 -90 -51
Depreciation Expense		 0.99 0.30 0.28
Amortization Expense		 -18 -5.98 -0.91
Non-Cash Adjustments To Reconcile Net Income		 20 8.85 2.86
Changes in Operating Assets and Liabilities, net		 2.96 7.24 2.97
Net Cash From Investing Activities		 -359 -268 -62
Net Cash From Continuing Investing Activities		 -359 -268 -62
Purchase of Property, Plant & Equipment		 -1.29 -2.17 -0.16
Purchase of Investments		 -703 -417 -123
Sale and/or Maturity of Investments		 345 151 62
Net Cash From Financing Activities		 515 452 29
Net Cash From Continuing Financing Activities		 515 452 29
Repayment of Debt		 -1.80 -22 -
Issuance of Common Equity		 515 472 0.00
Other Financing Activities, net		 1.85 0.80 0.03

Quarterly Cash Flow Statements for Structure Therapeutics

This table details how cash moves in and out of Structure Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -17 -2.62 -209 284 -32 79 10 -86 100 -2.00 -27
Net Cash From Operating Activities		 -52 -36 -20 -26 -34 -22 -21 -17 -20 -12 -10
Net Cash From Continuing Operating Activities		 -52 -36 -20 -26 -34 -22 -20 -17 -20 -12 -10
Net Income / (Loss) Continuing Operations		 -47 -36 -34 -26 -26 -25 -24 -23 -18 -12 -12
Consolidated Net Income / (Loss)		 -47 -36 -34 -26 -26 -25 -24 -23 -18 -12 -12
Depreciation Expense		 0.27 0.27 0.27 0.23 0.22 0.07 0.08 0.07 0.07 0.07 0.08
Amortization Expense		 -5.20 -6.03 -5.98 -3.18 -3.28 -2.32 -1.66 -1.64 -0.35 -0.48 -0.28
Non-Cash Adjustments To Reconcile Net Income		 6.33 6.30 7.07 3.85 3.18 2.31 2.13 1.79 2.62 0.70 0.72
Changes in Operating Assets and Liabilities, net		 -6.80 -0.53 13 -1.26 -8.17 2.72 3.03 6.17 -4.67 -0.44 1.42
Net Cash From Investing Activities		 34 33 -189 -205 1.42 -181 30 -69 -49 10 -17
Net Cash From Continuing Investing Activities		 34 33 -189 -205 1.42 -181 30 -69 -49 10 -17
Purchase of Property, Plant & Equipment		 -0.31 -0.02 -0.69 -0.43 -0.16 -1.16 -0.82 -0.19 0.00 -0.07 -0.07
Purchase of Investments		 -116 -132 -255 -284 -32 -237 -15 24 -190 -9.19 -46
Sale and/or Maturity of Investments		 150 166 66 80 34 57 46 -93 141 20 29
Net Cash From Financing Activities		 0.81 0.62 -0.76 515 0.70 282 0.47 -0.30 170 -0.32 -0.26
Net Cash From Continuing Financing Activities		 0.81 0.62 -0.76 515 0.70 282 0.47 -0.30 170 -0.32 -0.26
Repayment of Debt		 0.00 - -1.15 -0.59 -0.05 -18 - -0.48 -2.60 - -0.29
Issuance of Common Equity		 0.00 0.39 - 515 0.00 300 - - 172 - -
Other Financing Activities, net		 0.81 0.22 0.40 0.48 0.76 0.12 0.47 0.18 0.03 - 0.03

Annual Balance Sheets for Structure Therapeutics

This table presents Structure Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets		 903 482 98
Total Current Assets		 891 474 93
Cash & Equivalents		 170 130 26
Short-Term Investments		 714 338 65
Prepaid Expenses		 7.69 6.29 2.25
Plant, Property, & Equipment, net		 3.48 3.23 1.03
Total Noncurrent Assets		 8.64 5.18 3.73
Other Noncurrent Operating Assets		 8.64 5.18 3.73
Total Liabilities & Shareholders' Equity		 903 482 98
Total Liabilities		 38 29 13
Total Current Liabilities		 36 25 13
Accounts Payable		 8.02 4.74 6.01
Accrued Expenses		 26 19 6.74
Other Current Liabilities		 1.70 1.44 0.26
Total Noncurrent Liabilities		 2.47 4.31 0.00
Other Noncurrent Operating Liabilities		 2.47 4.31 0.00
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 865 453 -115
Total Preferred & Common Equity		 865 453 -115
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 865 453 -115
Common Stock		 1,193 659 1.92
Retained Earnings		 -329 -207 -117
Accumulated Other Comprehensive Income / (Loss)		 0.91 0.52 -0.11

Quarterly Balance Sheets for Structure Therapeutics

This table presents Structure Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023
Total Assets		 867 933 947 457 216 229 247
Total Current Assets		 850 924 938 449 210 228 246
Cash & Equivalents		 152 172 382 98 51 41 126
Short-Term Investments		 685 743 545 339 155 184 114
Prepaid Expenses		 13 8.37 11 13 4.54 3.64 5.29
Plant, Property, & Equipment, net		 3.52 3.74 3.32 3.12 2.41 1.08 0.96
Total Noncurrent Assets		 13 5.83 6.09 4.75 4.00 0.13 0.24
Other Noncurrent Operating Assets		 13 5.83 6.09 4.75 4.00 0.13 0.24
Total Liabilities & Shareholders' Equity		 867 933 947 457 216 229 247
Total Liabilities		 42 36 26 27 23 15 11
Total Current Liabilities		 36 33 23 24 20 15 11
Accounts Payable		 8.71 8.45 2.21 6.54 3.32 5.70 4.95
Accrued Expenses		 25 23 19 15 16 9.24 5.89
Other Current Liabilities		 2.47 1.71 1.63 1.60 0.82 0.07 0.17
Total Noncurrent Liabilities		 5.42 2.98 3.34 3.82 3.32 0.00 0.00
Other Noncurrent Operating Liabilities		 5.42 2.98 3.34 3.82 3.32 - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 825 897 921 430 193 214 236
Total Preferred & Common Equity		 825 897 921 430 193 214 236
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 825 897 921 430 193 214 236
Common Stock		 1,200 1,187 1,180 663 375 373 371
Retained Earnings		 -376 -293 -259 -233 -182 -158 -135
Accumulated Other Comprehensive Income / (Loss)		 0.82 2.84 -0.49 -0.09 -0.31 -0.39 0.15

Annual Metrics And Ratios for Structure Therapeutics

This table displays calculated financial ratios and metrics derived from Structure Therapeutics' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 -62.00% -103.90% 0.00%
EBIT Growth		 -53.96% -95.53% 0.00%
NOPAT Growth		 -53.96% -95.53% 0.00%
Net Income Growth		 -36.72% -74.63% 0.00%
EPS Growth		 3.70% 85.30% 0.00%
Operating Cash Flow Growth		 -46.73% -72.35% 0.00%
Free Cash Flow Firm Growth		 -67.38% 0.00% 0.00%
Invested Capital Growth		 -30.08% -139.04% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.53% -22.45% 0.00%
EBIT Q/Q Growth		 -11.30% -21.29% 0.00%
NOPAT Q/Q Growth		 -11.30% -21.29% 0.00%
Net Income Q/Q Growth		 -10.83% -16.40% 0.00%
EPS Q/Q Growth		 -8.33% 55.49% 0.00%
Operating Cash Flow Q/Q Growth		 -14.46% -13.90% 0.00%
Free Cash Flow Firm Q/Q Growth		 -13.86% 0.00% 0.00%
Invested Capital Q/Q Growth		 -1.03% -15.22% 0.00%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.25% 100.26% 100.03%
Interest Burden Percent		 77.24% 86.97% 97.61%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -18.60% -33.33% -60.50%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -18.60% -20.94% 82.11%
Return on Equity Simple (ROE_SIMPLE)		 -14.17% -19.79% 44.57%
Net Operating Profit after Tax (NOPAT)		 -111 -72 -37
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.74% -6.33% -15.99%
Return On Investment Capital (ROIC_SIMPLE)		 -12.81% -15.88% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -158 -103 -53
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -176 -108 -53
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 4.95 9.92 0.00
Price to Tangible Book Value (P/TBV)		 4.95 9.92 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.04 -1.07
Leverage Ratio		 1.05 1.08 1.15
Compound Leverage Factor		 0.81 0.94 1.13
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 235.72%
Common Equity to Total Capital		 100.00% 100.00% -135.72%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 66.82 92.58 4.97
Noncontrolling Interest Sharing Ratio		 0.00% 37.18% 235.72%
Liquidity Ratios		 - - -
Current Ratio		 24.74 19.14 7.16
Quick Ratio		 24.53 18.89 6.98
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -106 -64 0.00
Operating Cash Flow to CapEx		 -9,041.55% -3,668.11% -29,754.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -19 -14 -6.01
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.32 -8.35 0.00
Enterprise Value (EV)		 3,399 4,024 270
Market Capitalization		 4,283 4,492 161
Book Value per Share		 $5.03 $3.26 ($12.01)
Tangible Book Value per Share		 $5.03 $3.26 ($12.01)
Total Capital		 865 453 85
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -884 -467 -91
Capital Expenditures (CapEx)		 1.29 2.17 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -28 -18 -11
Debt-free Net Working Capital (DFNWC)		 855 449 80
Net Working Capital (NWC)		 855 449 80
Net Nonoperating Expense (NNE)		 12 18 15
Net Nonoperating Obligations (NNO)		 -884 -467 -91
Total Depreciation and Amortization (D&A)		 -17 -5.68 -0.63
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($0.78) ($0.81) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 157.92M 110.20M 0.00
Adjusted Diluted Earnings per Share		 ($0.78) ($0.81) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 157.92M 110.20M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 172.03M 139.79M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -111 -72 -37
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -4.91%

Quarterly Metrics And Ratios for Structure Therapeutics

This table displays calculated financial ratios and metrics derived from Structure Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -74.61% -58.86% -85.92% -31.61% -76.01% -148.81% -114.99% -98.24% -54.67% 0.00% 0.00%
EBIT Growth		 -75.89% -51.84% -75.31% -28.20% -62.93% -139.23% -105.98% -86.15% -51.71% 0.00% 0.00%
NOPAT Growth		 -75.89% -51.84% -75.31% -28.20% -62.93% -139.23% -105.98% -86.15% -51.71% 0.00% 0.00%
Net Income Growth		 -79.88% -48.88% -42.39% -11.83% -44.85% -106.34% -92.17% -66.91% -37.41% 0.00% 0.00%
EPS Growth		 -42.11% -40.00% 4.76% 10.00% 24.00% 87.07% 83.46% 87.80% 82.64% 0.00% 0.00%
Operating Cash Flow Growth		 -53.25% -67.83% 4.19% -56.23% -67.82% -80.68% -96.14% -67.35% -50.23% 0.00% 0.00%
Free Cash Flow Firm Growth		 -66.60% -114.50% -346.12% -241.77% -119.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Growth		 -84.65% -30.08% -48.35% 40.16% -47.00% -139.04% 0.00% 0.00% 0.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -15.94% -2.45% -42.14% -3.42% -5.49% -19.90% -0.62% -38.30% -49.12% -3.61% 7.22%
EBIT Q/Q Growth		 -19.66% -2.67% -37.58% -4.06% -3.29% -18.55% -0.61% -32.26% -51.66% -2.07% 9.08%
NOPAT Q/Q Growth		 -19.66% -2.67% -37.58% -4.06% -3.29% -18.55% -0.61% -32.26% -51.66% -2.07% 9.08%
Net Income Q/Q Growth		 -28.38% -7.36% -30.51% 0.01% -6.26% -2.69% -2.50% -29.51% -51.37% 4.37% 10.98%
EPS Q/Q Growth		 -28.57% -5.00% -11.11% 5.26% -26.67% 28.57% -5.00% 20.00% 78.45% 8.66% 22.56%
Operating Cash Flow Q/Q Growth		 -43.22% -85.15% 25.37% 22.56% -56.84% -5.70% -21.68% 16.81% -68.87% -14.74% -3.82%
Free Cash Flow Firm Q/Q Growth		 -18.10% -9.84% 4.91% -35.07% -52.05% -128.45% 27.15% 13.25% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 34.44% -1.03% -203.68% 8.20% 53.81% -15.22% -22.49% -125.49% 24.89% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.21% 100.37% 100.27% 100.20% 100.11% 98.74% 101.73% 100.51% 100.14% 98.51% 100.59%
Interest Burden Percent		 82.99% 77.23% 73.93% 77.98% 81.23% 80.06% 89.72% 89.13% 91.35% 93.05% 97.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -22.85% -18.60% -20.29% -17.69% -29.33% -33.33% -39.90% -30.57% -23.78% -60.50% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -22.85% -18.60% -20.29% -17.69% -29.33% -20.94% -39.90% -30.57% -23.78% 82.11% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -17.38% 0.00% -12.33% -10.90% -22.73% 0.00% -39.90% -30.57% -23.78% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -39 -33 -32 -23 -22 -22 -18 -18 -14 -9.07 -8.89
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.16% -0.52% -0.34% -0.47% -1.07% -1.01% -5.41% -4.53% -3.50% -3.09% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -4.78% -3.81% - - - -4.79% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -56 -47 -46 -33 -32 -31 -26 -26 -20 -13 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -61 -53 -52 -36 -35 -33 -28 -28 -20 -13 -13
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.61 4.95 8.40 6.32 13.93 9.92 30.04 22.25 7.21 0.00 0.00
Price to Tangible Book Value (P/TBV)		 3.61 4.95 8.40 6.32 13.93 9.92 30.04 22.25 7.21 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.03 -1.01 -1.02 -1.04 -1.06 -1.05 -1.02 -1.07 0.00
Leverage Ratio		 1.06 1.05 1.05 1.04 1.06 1.08 1.12 1.07 1.05 1.15 0.00
Compound Leverage Factor		 0.88 0.81 0.78 0.81 0.86 0.86 1.01 0.95 0.96 1.07 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 235.72% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -135.72% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 42.94 67.22 124.66 135.02 131.26 93.07 148.05 190.43 93.08 6.30 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 37.18% 0.00% 0.00% 0.00% 235.72% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 23.29 24.74 27.63 41.38 19.05 19.14 10.45 15.20 22.37 7.16 0.00
Quick Ratio		 22.94 24.53 27.38 40.92 18.50 18.89 10.22 14.96 21.89 6.98 0.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -34 -29 -26 -27 -20 -13 -5.84 -8.02 -9.24 0.00 0.00
Operating Cash Flow to CapEx		 -16,633.44% -227,918.75% -2,875.33% -6,181.03% -21,037.04% -1,879.67% -2,506.95% -8,845.03% 0.00% -16,938.03% -14,556.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 -19 -18 -6.09 -6.63 -14 -12 -10 -4.51 -6.01 0.00
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -5.61 -4.32 -6.03 4.09 -2.12 -8.35 -12 -10 -4.51 0.00 0.00
Enterprise Value (EV)		 2,141 3,399 6,618 4,894 5,552 4,024 5,590 4,546 1,464 270 0.00
Market Capitalization		 2,978 4,283 7,533 5,821 5,988 4,492 5,796 4,771 1,705 161 161
Book Value per Share		 $4.79 $5.03 $5.23 $6.59 $3.07 $3.26 $1.68 $1.87 $3.30 ($12.01) $0.00
Tangible Book Value per Share		 $4.79 $5.03 $5.23 $6.59 $3.07 $3.26 $1.68 $1.87 $3.30 ($12.01) $0.00
Total Capital		 825 865 897 921 430 453 193 214 236 85 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -837 -884 -915 -927 -436 -467 -205 -225 -241 -91 0.00
Capital Expenditures (CapEx)		 0.31 0.02 0.69 0.43 0.16 1.16 0.82 0.19 0.00 0.07 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -24 -28 -25 -12 -11 -18 -16 -11 -5.71 -11 0.00
Debt-free Net Working Capital (DFNWC)		 813 855 890 915 426 449 190 213 235 80 0.00
Net Working Capital (NWC)		 813 855 890 915 426 449 190 213 235 80 0.00
Net Nonoperating Expense (NNE)		 7.42 3.54 1.89 2.71 3.63 2.81 5.56 5.09 4.22 2.81 3.53
Net Nonoperating Obligations (NNO)		 -837 -884 -915 -927 -436 -467 -205 -225 -241 -91 0.00
Total Depreciation and Amortization (D&A)		 -4.92 -5.75 -5.71 -2.95 -3.06 -2.25 -1.58 -1.57 -0.28 -0.41 -0.20
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.27) ($0.21) ($0.20) ($0.18) ($0.19) ($0.15) ($0.21) $0.00 ($0.25) ($1.16) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 172.05M 157.92M 171.63M 148.24M 139.71M 110.20M 114.95M 0.00 71.66M 9.58M 0.00
Adjusted Diluted Earnings per Share		 ($0.27) ($0.21) ($0.20) ($0.18) ($0.19) ($0.15) ($0.21) $0.00 ($0.25) ($1.16) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 172.05M 157.92M 171.63M 148.24M 139.71M 110.20M 114.95M 0.00 71.66M 9.58M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 172.61M 172.03M 171.78M 171.59M 139.86M 139.79M 139.16M 0.00 114.80M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -39 -33 -32 -23 -22 -22 -18 -18 -14 -9.07 -8.89
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.91% 0.00%

Frequently Asked Questions About Structure Therapeutics' Financials

When does Structure Therapeutics's financial year end?

According to the most recent income statement we have on file, Structure Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Structure Therapeutics' net income changed over the last 2 years?

Structure Therapeutics' net income appears to be on an upward trend, with a most recent value of -$122.53 million in 2024, rising from -$51.32 million in 2022. The previous period was -$89.62 million in 2023. See where experts think Structure Therapeutics is headed by visiting Structure Therapeutics' forecast page.

What is Structure Therapeutics's operating income?
Structure Therapeutics's total operating income in 2024 was -$158.23 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $158.23 million
How has Structure Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Structure Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Structure Therapeutics have?

Structure Therapeutics' total liabilities were at $38.49 million at the end of 2024, a 32.5% increase from 2023, and a 195.8% increase since 2022.

How much cash does Structure Therapeutics have?

In the past 2 years, Structure Therapeutics' cash and equivalents has ranged from $26.09 million in 2022 to $169.51 million in 2024, and is currently $169.51 million as of their latest financial filing in 2024.

How has Structure Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Structure Therapeutics' book value per share changed from -12.01 in 2022 to 5.03 in 2024, a change of -141.9%.


Related Companies

This page (NASDAQ:GPCR) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...
Crypto 101 Media | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...
Weiss Ratings | Sponsored